Abstract
participation in the study receiving LY in combination with gemcitabine or pemetrexed. Conclusions: Despite the upper end of the 90% RCI for the desipramine Cmax LSM ratio being slightly greater than 1.25, it is not expected that this minimal change in Cmax (with no change in AUC ratios) would lead to any clinically significant CYP2D6 drug interactions. Therefore, no exclusion criteria for concomitant medications metabolized by CYP2D6 would likely be needed for Phase 3 studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
